Hims & Hers (HIMS) Q4 FY25 earnings call

Earnings call· Dec 2025 (Q4 FY25)· Health Care· Feb 23, 2026

Source: earnings call transcript

Hims & Hers delivered strong Q4 FY25 results, driven by subscriber growth and expansion across specialties, with full-year revenue up 59% and adjusted EBITDA up 80%. The company is strategically investing in international markets, new offerings like Labs and hormonal therapies, and technology, including AI and diagnostics, to build a comprehensive, consumer-centric healthcare platform. While Q1 FY26 guidance reflects near-term headwinds from shipping cadence changes and Super Bowl ad spend, management remains confident in its long-term growth and profitability targets, leveraging its domestic

You’re reading a preview. Opening the full call uses 1 concall credit.

HIMS operating KPIs by quarter

HIMS operating KPIs stated on its earnings calls, by fiscal quarter
KPI	This call Dec 2025 Q4 FY25	Mar 2026 Q1 FY26	Change vs prior quarter
Subscribers	2.5M+ At the end of 2025, over 2.5 million subscribers on our platform were benefiting from our pursuit of this vision. Source: earnings call transcript	<2.6M In the first quarter, revenue grew 4% year-over-year to $608 million, subscribers grew 9% year-over-year to nearly 2.6 million and adjusted EBITDA was $44 million, representing a 7% adjusted EBITDA margin. Source: earnings call transcript	—

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.